Tirzepatide Dosage Guide: Dual Agonist Reconstitution, Escalation Protocol & Syringe Units
Tirzepatide dosing guide: GIP + GLP-1 dual agonist mechanism, SURMOUNT trial weight loss data, dose escalation protocol, and reconstitution calculator.
TL;DR
- Tirzepatide is a GLP-1/GIP dual agonist that simultaneously activates both incretin receptor systems for enhanced metabolic effects
- The SURMOUNT-1 phase 3 trial demonstrated a mean weight reduction of approximately 22.5% at 15 mg/week — the largest reported weight loss for any pharmaceutical agent to date
- Research protocols use a structured escalation: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, advancing every 4 weeks
- Once-weekly subcutaneous dosing; half-life approximately 5 days
- Use the Tirzepatide Reconstitution Calculator →
⚠️ Disclaimer: This article is written for educational and research purposes only. Tirzepatide (brand name Mounjaro/Zepbound) is an FDA-approved prescription medication for type 2 diabetes and obesity management, and a regulated research compound in other contexts. Nothing in this article constitutes medical advice. All dosing information is based on published clinical research. Consult a licensed healthcare professional before making any decisions related to tirzepatide.
Tirzepatide is a GLP-1/GIP dual receptor agonist administered once weekly via subcutaneous injection. Research doses escalate from 2.5 mg/week up to 15 mg/week. The most common research vial is 5 mg reconstituted in 1 mL BAC water (5 mg/mL).
| Vial Size | BAC Water | Concentration | 2.5 mg dose | 5 mg dose | 10 mg dose | 15 mg dose |
|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 0.5 mL (50 units) | 1.0 mL (100 units) | — | — |
| 10 mg | 1 mL | 10 mg/mL | 0.25 mL (25 units) | 0.5 mL (50 units) | 1.0 mL (100 units) | — |
| 15 mg | 1 mL | 15 mg/mL | 0.167 mL (16.7 units) | 0.333 mL (33.3 units) | 0.667 mL (66.7 units) | 1.0 mL (100 units) |
All unit values assume a standard U-100 insulin syringe (100 units = 1 mL). Doses requiring >1 mL should use a standard 1–3 mL syringe.
Calculate tirzepatide syringe units →
Tirzepatide Escalation Protocol: 2.5 mg to 15 mg Over 20 Weeks
Rapid dose escalation with tirzepatide produces significant nausea, vomiting, and GI discomfort. The standard protocol advances in 2.5 mg increments every 4 weeks:
| Phase | Week Range | Dose | Notes |
|---|---|---|---|
| Initiation | Weeks 1–4 | 2.5 mg/week | Tolerability assessment; GI adaptation phase |
| Escalation 1 | Weeks 5–8 | 5.0 mg/week | First therapeutic dose; some subjects maintain here |
| Escalation 2 | Weeks 9–12 | 7.5 mg/week | Advance only if tolerating previous dose well |
| Escalation 3 | Weeks 13–16 | 10.0 mg/week | Strong efficacy dose; many protocols stop here |
| Escalation 4 | Weeks 17–20 | 12.5 mg/week | Intermediate step before maximum dose |
| Maintenance | Week 21+ | 15.0 mg/week | Maximum studied dose in SURMOUNT program |
Escalation should only proceed if the current dose is well-tolerated. If side effects are significant, extend the current dose phase by an additional 4 weeks before attempting to advance. Not all research questions require reaching the maximum dose — many metabolic mechanism studies are conducted at 5–10 mg.
What Makes Tirzepatide Different?
Most GLP-1 receptor agonists — semaglutide, liraglutide, exenatide — work by binding to a single target: the GLP-1 receptor. Tirzepatide is structurally and pharmacologically distinct because it is a single molecule that activates two different receptors: the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.
This dual activity is not simply "GLP-1 agonist plus GIP agonist." Tirzepatide is engineered as a twincretin — a single 39-amino acid peptide with a molecular architecture derived from the native GIP sequence, modified to also engage the GLP-1 receptor with high affinity. The GIP-based backbone gives tirzepatide some structural advantages: GIP receptor signaling has distinct downstream pathways compared to GLP-1 receptor signaling, and the natural GIP sequence is somewhat less susceptible to the nausea-inducing effects that limit dose escalation with pure GLP-1 agonists.
Tirzepatide also incorporates a C20 fatty diacid modification that enables albumin binding, extending its plasma half-life to approximately 5 days — long enough to support once-weekly dosing.
Dual Agonist Mechanism: GLP-1 + GIP Synergy
To understand why tirzepatide produces substantially greater weight loss than GLP-1 single agonists, it helps to understand what the GIP receptor contributes to metabolic regulation.
GLP-1 receptor activation (shared with semaglutide and liraglutide) produces:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Glucagon suppression from pancreatic alpha cells
- Slowed gastric emptying, increasing satiety
- Appetite suppression via hypothalamic GLP-1R signaling
- Reduced caloric intake through CNS pathways
GIP receptor activation (unique to tirzepatide in this compound class) adds:
- Enhanced glucose-dependent insulin secretion via a distinct signaling pathway (Gs/cAMP)
- Improved beta-cell function and potentially beta-cell mass preservation
- Direct effects on adipose tissue: GIP receptors are expressed on adipocytes, and GIP receptor signaling influences fatty acid storage, lipolysis, and adipokine secretion
- Potential enhancement of GLP-1 receptor sensitivity — research suggests that GIP receptor co-activation may upregulate GLP-1 receptor expression, amplifying the GLP-1 component of the response
The adipose tissue effects of GIP receptor agonism are particularly significant. In lean states, GIP promotes lipid storage; however, tirzepatide's GIP component in the context of caloric restriction and GLP-1 co-agonism appears to shift adipose metabolism toward increased energy expenditure and lipolysis, though the exact mechanism remains an active research area.
Phase 3 SURMOUNT Trial Data
The SURMOUNT-1 trial (published in the New England Journal of Medicine, 2022) enrolled 2,539 adults with a BMI of 30 or greater (or 27+ with weight-related comorbidity) who did not have type 2 diabetes. Participants received weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks with lifestyle intervention.
| Tirzepatide Dose | Mean Weight Loss (%) | Mean Weight Loss (kg) | % Achieving ≥5% loss | % Achieving ≥20% loss |
|---|---|---|---|---|
| 5 mg/week | -16.0% | -15.7 kg | 89% | 37% |
| 10 mg/week | -21.4% | -19.9 kg | 96% | 55% |
| 15 mg/week | -22.5% | -20.9 kg | 96% | 63% |
| Placebo | -2.4% | -2.3 kg | 28% | 3% |
These results represented a watershed moment in metabolic research. For context, semaglutide 2.4 mg/week — the previous benchmark — produced approximately 14.9% mean weight loss in the STEP-1 trial. Tirzepatide's 15 mg data exceeds this by approximately 7.5 percentage points in absolute terms, and 50% in relative terms.
The SURMOUNT-2 trial replicated these findings in subjects with type 2 diabetes (who typically show attenuated weight loss responses to GLP-1 compounds), demonstrating 15.7% mean weight loss at 15 mg — still substantially above what had been achieved with prior agents in this population.
Reconstitution Scenarios
Tirzepatide for research is typically supplied as lyophilized powder in 5mg or 10mg vials. The following tables provide complete reconstitution reference data for both vial sizes.
5 mg Vial Reconstitution
| BAC Water Added | Concentration | Volume per 2.5 mg dose | Volume per 5 mg dose |
|---|---|---|---|
| 1.0 mL | 5,000 mcg/mL | 0.5 mL (50 units) | 1.0 mL (100 units) |
| 2.0 mL | 2,500 mcg/mL | 1.0 mL (100 units) | 2.0 mL* |
| 2.5 mL | 2,000 mcg/mL | 1.25 mL* | 2.5 mL* |
10 mg Vial Reconstitution
| BAC Water Added | Concentration | Volume per 5 mg dose | Volume per 10 mg dose |
|---|---|---|---|
| 2.0 mL | 5,000 mcg/mL | 1.0 mL (100 units) | 2.0 mL* |
| 4.0 mL | 2,500 mcg/mL | 2.0 mL* | 4.0 mL* |
| 1.0 mL | 10,000 mcg/mL | 0.5 mL (50 units) | 1.0 mL (100 units) |
Volumes exceeding 1 mL should be administered using a standard 1 mL or 3 mL syringe rather than an insulin syringe. For subcutaneous injection, volumes above 1 mL may be split between 2 injection sites to improve comfort.
Practical recommendation: For the 2.5 mg initiation dose from a 5 mg vial, reconstituting in 1.0 mL gives 5,000 mcg/mL, allowing a clean 0.5 mL draw. For the 5 mg dose from the same setup, the draw is a clean 1.0 mL. As you escalate to higher doses, 10 mg vials reconstituted in 2.0 mL (5,000 mcg/mL) minimize injection volumes.
Comparison with Semaglutide
For full semaglutide dosing and reconstitution details, see the semaglutide dosage guide.
| Parameter | Tirzepatide | Semaglutide 2.4 mg |
|---|---|---|
| Receptor Targets | GLP-1 + GIP | GLP-1 only |
| Half-Life | ~5 days | ~7 days |
| Dosing Frequency | Once weekly | Once weekly |
| Maximum Research Dose | 15 mg/week | 2.4 mg/week |
| SURMOUNT-1 / STEP-1 Weight Loss | ~22.5% (15 mg) | ~14.9% (2.4 mg) |
| Escalation Duration | ~20 weeks to max | ~16 weeks to max |
| Nausea Incidence (clinical) | ~30–35% (any grade) | ~20–25% (any grade) |
| CV Outcome Trial Data | SURPASS-CVOT ongoing | SELECT trial (positive) |
For a more detailed comparison of the full GLP-1 compound class, see the GLP-1 Peptides Comparison Guide →. Researchers interested in the next generation of incretin compounds should also review the retatrutide dosage guide, which covers the GLP-1/GIP/glucagon triple agonist class.
Frequently Asked Questions About Tirzepatide
Q: What is tirzepatide and how does it work? A: Tirzepatide is a 39-amino acid synthetic peptide that functions as a dual agonist for both the GLP-1 and GIP incretin receptors simultaneously. It is based structurally on the native GIP sequence with modifications enabling GLP-1 receptor co-activation, and a C20 fatty diacid modification that enables albumin binding for an approximately 5-day half-life. By stimulating both receptor pathways, tirzepatide produces enhanced insulin secretion, appetite suppression, slowed gastric emptying, and direct effects on adipose tissue metabolism that go beyond what single GLP-1 agonists achieve.
Q: How much weight loss does tirzepatide cause in research? A: In the SURMOUNT-1 phase 3 trial, tirzepatide at 15 mg/week produced a mean weight loss of 22.5% over 72 weeks — the largest weight reduction demonstrated for any pharmaceutical agent in a controlled trial at the time of publication. The 10 mg dose produced approximately 21.4% and the 5 mg dose approximately 16.0% mean weight loss. For context, semaglutide 2.4 mg/week produced approximately 14.9% mean weight loss in the STEP-1 trial.
Q: What is the tirzepatide escalation protocol? A: The standard escalation protocol begins at 2.5 mg/week for 4 weeks as a tolerability phase, then advances in 2.5 mg increments every 4 weeks: 5 mg (weeks 5–8), 7.5 mg (weeks 9–12), 10 mg (weeks 13–16), 12.5 mg (weeks 17–20), and 15 mg (week 21+) as the maximum studied dose. Escalation should only proceed if the current dose is well-tolerated — GI side effects including nausea and vomiting are the primary adverse events and are most pronounced during rapid dose increases.
Q: How do you reconstitute tirzepatide? A: Tirzepatide is supplied as a lyophilized powder in 5 mg or 10 mg vials and is reconstituted with bacteriostatic water. For a 5 mg vial with 1.0 mL BAC water, concentration is 5,000 mcg/mL — the 2.5 mg initiation dose equals a clean 0.5 mL draw, and the 5 mg dose equals 1.0 mL. For higher doses (7.5 mg and above), a 10 mg vial reconstituted in 1.0 mL (10,000 mcg/mL) keeps volumes at or below 1.0 mL for doses up to 10 mg.
Q: How does tirzepatide compare to semaglutide? A: Tirzepatide produces approximately 50% greater mean weight loss than semaglutide in comparative trial data (22.5% vs 14.9%), which is attributed to the additional GIP receptor activation and its effects on adipose tissue metabolism. Tirzepatide has a slightly shorter half-life (~5 days vs ~7 days) but both support once-weekly dosing. Semaglutide has a more extensive cardiovascular outcomes trial dataset (SELECT trial showed significant MACE reduction), while tirzepatide's SURPASS-CVOT data is still accumulating. Semaglutide is also FDA-approved for cardiovascular risk reduction in addition to diabetes and obesity.
Calculate your Tirzepatide reconstitution → Reconstitution Calculator | Half-Life Calculator
This content is provided for educational and research informational purposes only. Tirzepatide is an FDA-approved prescription medication (Mounjaro for T2D, Zepbound for obesity) and is a regulated compound. Use outside of licensed medical practice or authorized research contexts may be subject to legal restrictions. This article does not constitute medical advice.
Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.
Written by the Peptide Performance Calculator Research Team
Our team compiles research guides based on published literature for educational purposes. All content is for research use only — not medical advice. Read our disclaimer.
Frequently Asked Questions
What is tirzepatide?
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1 and GIP receptor agonist approved by the FDA for type 2 diabetes and obesity. SURMOUNT-1 trials showed up to 22.5% body weight loss at 72 weeks.
What is the tirzepatide escalation protocol?
Standard escalation: 2.5 mg/week for 4 weeks → 5 mg/week for 4 weeks → 7.5 mg/week → 10 mg/week → 12.5 mg/week → maintenance at 15 mg/week. Each step is 4 weeks.
How do I reconstitute research tirzepatide?
Common setup: add 2 mL bacteriostatic water to a 10 mg vial (5,000 mcg/mL). A 2.5 mg (2,500 mcg) starting dose = 50 units on a U-100 syringe. Use the reconstitution calculator for your vial size.
How does tirzepatide differ from semaglutide?
Semaglutide is GLP-1 only. Tirzepatide adds GIP receptor agonism, which appears to enhance fat tissue breakdown and improve insulin sensitivity through a complementary pathway. SURMOUNT data showed greater weight loss for tirzepatide.
New compound guides and calculator updates — no spam, unsubscribe any time.
Free Peptide Calculators
7 free calculators covering reconstitution, dosage, syringe units, half-life, injection volume, stack planning, and cycle duration — no account needed.